Who Buys Cladribine from India — 62 Importers Behind a $232.8K Market

Cladribine, an antineoplastic agent used primarily in the treatment of certain types of leukemia and multiple sclerosis, is imported from India by a diverse range of buyers. These buyers can be classified into the following segments:

1. Distributors: Entities that purchase Cladribine in bulk to supply to various healthcare providers. For instance, BLUE POINT in Lebanon and SHIYUN in Singapore likely function as distributors, given their significant import volumes. Distributors typically place large, periodic orders to maintain a steady supply chain for their clients.

2. Hospital Groups: Large healthcare institutions or networks that procure Cladribine directly for patient treatment. While specific hospital groups are not identified in the top buyers, it's common for such entities to import pharmaceuticals directly to ensure quality control and cost-effectiveness. Their purchasing patterns often involve regular, sizable orders aligned with patient treatment schedules.

3. Retail Chains: Pharmacy chains that import Cladribine to dispense to patients. The data does not specify retail chains among the top buyers; however, such entities usually order smaller quantities more frequently, based on consumer demand.

4. Government Procurement: National health agencies or international organizations like UNICEF and the Global Fund that procure medicines for public health programs. The data does not indicate direct government procurement among the top buyers, but such entities typically engage in large-scale, tender-based purchasing to supply public healthcare facilities.

5. Re-exporters: Companies that import Cladribine with the intent to export it to other markets. ARROW GENERAL TRADING FZE in the United Arab Emirates may serve as a re-exporter, leveraging the UAE's strategic location as a trade hub. Re-exporters often have irregular purchasing patterns, influenced by market demands in their target export destinations.

6. Contract Manufacturers: Firms that import Cladribine as an active pharmaceutical ingredient (API) for formulation into finished products. The provided data does not specify contract manufacturers among the top buyers. These entities typically order raw materials in bulk, aligned with production schedules and client contracts.

Understanding the import regulations for Cladribine in the top importing countries is crucial for market entry and compliance. Below is an overview for Lebanon, Malaysia, Singapore, the United Arab Emirates, and Mexico:

The demand for Cladribine in importing countries is primarily driven by the prevalence of multiple sclerosis (MS) and certain types of leukemia, for which Cladribine is an approved treatment. The inclusion of Cladribine in the World Health Organization's (WHO) Model List of Essential Medicines in July 2023 underscores its therapeutic importance and encourages its adoption in national treatment guidelines. (who.int)

Government healthcare programs and the expansion of universal health coverage in countries like Malaysia and the UAE have increased access to essential medicines, including Cladribine. Tender-based purchasing systems, often utilized by public health sectors, facilitate the procurement of such medicines, ensuring availability in public healthcare facilities. The presence of 62 buyers across 29 countries, as per our data, indicates a broad and growing market for Cladribine, reflecting its recognized efficacy and the global commitment to addressing MS and leukemia.

Cladribine, an antineoplastic agent used primarily in the treatment of certain types of leukemia and multiple sclerosis, is imported from India by a diverse range of buyers. These buyers can be classified into the following segments:

1. Distributors: Entities that purchase Cladribine in bulk to supply to various healthcare providers. For instance, BLUE POINT in Lebanon and SHIYUN in Singapore likely function as distributors, given their significant import volumes. Distributors typically place large, periodic orders to maintain a steady supply chain for their clients.

2. Hospital Groups: Large healthcare institutions or networks that procure Cladribine directly for patient treatment. While specific hospital groups are not identified in the top buyers, it's common for such entities to import pharmaceuticals directly to ensure quality control and cost-effectiveness. Their purchasing patterns often involve regular, sizable orders aligned with patient treatment schedules.

3. Retail Chains: Pharmacy chains that import Cladribine to dispense to patients. The data does not specify retail chains among the top buyers; however, such entities usually order smaller quantities more frequently, based on consumer demand.

4. Government Procurement: National health agencies or international organizations like UNICEF and the Global Fund that procure medicines for public health programs. The data does not indicate direct government procurement among the top buyers, but such entities typically engage in large-scale, tender-based purchasing to supply public healthcare facilities.

5. Re-exporters: Companies that import Cladribine with the intent to export it to other markets. ARROW GENERAL TRADING FZE in the United Arab Emirates may serve as a re-exporter, leveraging the UAE's strategic location as a trade hub. Re-exporters often have irregular purchasing patterns, influenced by market demands in their target export destinations.

6. Contract Manufacturers: Firms that import Cladribine as an active pharmaceutical ingredient (API) for formulation into finished products. The provided data does not specify contract manufacturers among the top buyers. These entities typically order raw materials in bulk, aligned with production schedules and client contracts.

Understanding the import regulations for Cladribine in the top importing countries is crucial for market entry and compliance. Below is an overview for Lebanon, Malaysia, Singapore, the United Arab Emirates, and Mexico:

The demand for Cladribine in importing countries is primarily driven by the prevalence of multiple sclerosis (MS) and certain types of leukemia, for which Cladribine is an approved treatment. The inclusion of Cladribine in the World Health Organization's (WHO) Model List of Essential Medicines in July 2023 underscores its therapeutic importance and encourages its adoption in national treatment guidelines. (who.int)

Government healthcare programs and the expansion of universal health coverage in countries like Malaysia and the UAE have increased access to essential medicines, including Cladribine. Tender-based purchasing systems, often utilized by public health sectors, facilitate the procurement of such medicines, ensuring availability in public healthcare facilities. The presence of 62 buyers across 29 countries, as per our data, indicates a broad and growing market for Cladribine, reflecting its recognized efficacy and the global commitment to addressing MS and leukemia.